Markedsdata leveret af TwelveData og Morningstar
Biosergen AB is a clinical-stage biotechnology company advancing the treatment of life-threatening fungal infections. It has developed the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 is a drug in the field of antifungals because of its fungicidal effect (it kills the fungus), which is preferable to drugs with a fungistatic effect.